Market/Novel Tech Articles
Homology Medicine Inc., with plans to develop AAV gene therapies for ophthalmic disease, announce plans for a $100M IPO on the US NASDAQ
Homology Medicine Inc, a gene editing company based in Massachusetts, USA, has announced a $100M IPO on the US NASDAQ. The company uses its technology genome editing platform based on homologous receombination and delivered by AAV to develop treatments for a number of disorders. A Novemebr 2017 investment of $35M in Homology by Novartis AG […]Read full story
French company GenSight Biologics announces positive results for its Phase I/II clinical study of a gene therapy treatment for Leber Hereditary Optic Neuropathy
GenSight Biologics S.A. (Euronext: SIGHT) has announced the publication of the company’s clinical results from a Phase I/II study and long-term follow-up of an experimental gene therapy, ”GS010”, designed for the treatment of Leber Hereditary Optic Neuropathy (LHON). According to the company, the study demonstrated that GS010 (rAAV2/2-ND4) was safe and well tolerated 2 years […]Read full story
Novartis AG (NYSE: NVS; SIX: NOVN) attains ex-US rights to develop and commercialize new gene therapy treatment for Leber’s congenital amaurosis (LCA).
Spark Therapeutics Inc. (NASDAQ:ONCE) have announced that the company has entered into a licensing and supply agreement for investigational voretigene neparvovec, branded in the US as LUXTURNA, indicated for the treatment of patients with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy. The agreement is understood to include a $105 million upfront payment for Spark with an […]Read full story